Filing Flows › Amneal Pharmaceuticals (AMRX) › Q1 2026
Amneal Pharmaceuticals (AMRX) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
Amneal Pharmaceuticals (AMRX) reported revenue of $723M for the first quarter 2026 (Q1 2026), +4% from a year earlier and -11% from the quarter before. Operating margin was 19.6%, net earnings $62.3M (8.6% of revenue).
Amneal Pharmaceuticals, Q1 2026: revenue $723M (+4% year over year), operating margin 19.6%, net earnings $62.3M, operating cash flow −$26.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $723M | -11% | +4% |
| Gross profit | $320M | +8% | +25% |
| Operating profit | $142M | +27% | +41% |
| Net earnings | $62.3M | +77% | +411% |
| Operating cash flow | −$26.7M | -121% | -461% |
What changed
Revenue was $722.5M in Q1 2026, up 4% year over year and down 11% from the previous quarter.
Gross margin was 44.3%, up 7.5 points from Q1 2025. Operating profit was $141.8M, a 19.6% margin (up 5.2 points year over year). Of the extra revenue versus Q1 2025, 153% reached operating profit, above the 14% margin then. Operating expenses grew 15% against revenue growth of 4%. Net earnings were $62.3M, up 411% year over year. The effective tax rate was 2.7%.
Operating cash flow was −$26.7M. Non-cash charges added back $8.8M of share-based compensation. Working capital and other items used $113.6M. Capital expenditures of $8.2M exceeded it, leaving free cash flow of −$34.9M.
Questions
What was Amneal Pharmaceuticals' revenue in the first quarter 2026?
Amneal Pharmaceuticals (AMRX) reported revenue of $723M for the first quarter 2026 (Q1 2026), +4% from a year earlier and -11% from the quarter before.
Was Amneal Pharmaceuticals profitable in the first quarter 2026?
Operating profit was $142M (19.6% of revenue) and net earnings $62.3M.